Following on from information provided to NICE by the company in July 2020 the appraisal of Pembrolizumab in combination for untreated extensive-stage small-cell lung cancer [ID1509] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
Status | Discontinued |
Technology type | Medicine |
Decision | Selected |
Process | TA |
ID number | 1509 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
Date | Update |
---|---|
15 November 2022 | Following on from information provided to NICE by the company in July 2020 the appraisal of Pembrolizumab in combination for untreated extensive-stage small-cell lung cancer [ID1509] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
15 November 2022 | Discontinued. Following on from information provided to NICE by the company in July 2020 the appraisal of Pembrolizumab in combination for untreated extensive-stage small-cell lung cancer [ID1509] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
07 October 2020 | Committee meeting |
08 July 2020 | Suspended. Topic is suspended |
08 July 2020 | The company have announced that they will no longer be pursuing a Marketing Authorisation Application to the European Medicines Agency for Pembrolizumab with etoposide and a platinum-based compound for untreated extensive-stage small-cell lung cancer following the results of the KEYNOTE-604 trial data. Therefore NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred, NICE will continue to monitor any development and will update interested parties if the situation changes. |
07 February 2020 | The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of pembrolizumab in combination for untreated extensive-stage small-cell lung cancer. Please note that following on from advice received from the company the timelines for this appraisal will be confirmed. As this appraisal has been referred, NICE will continue to monitor any developments and will provide an update as and when the situation changes. |
05 December 2019 - 10 January 2020 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
09 December 2019 | The Department for Health and Social Care has asked NICE to conduct an appraisal of pembrolizumab with chemotherapy for untreated extensive-stage small-cell lung cancer. Please note that following on from advice received from the company the timelines for this appraisal have been revised. We now anticipate that the appraisal will begin during early- February 2020 when we will write to you about how you can get involved. |
05 December 2019 | Consultation on the draft scope and provisional matrix of consultees and commentators, with comments requested by 10 January 2020. |
08 July 2019 | As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of pembrolizumab with chemotherapy for untreated extensive-stage small-cell lung cancer. Following an update from the company further information on the timelines for this appraisal will be available in due course. |
22 March 2019 | In progress. As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of pembrolizumab with chemotherapy for untreated extensive-stage small-cell lung cancer. Please note that following on from advice received from the company the timelines for this appraisal have been revised. We now anticipate that the appraisal will begin during mid- July 2019 when we will write to you about how you can get involved. |
14 November 2018 - 12 December 2018 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
17 October 2018 | In progress. Topic referred |
For further information on our processes and methods, please see our CHTE processes and methods manual